Navigation Links
Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
Date:12/6/2007

molecules. Glenmark has 11 lead molecules at various stages of development in NCE & NBE research. Three of the leads are in Phase 2 whereas eight other leads are into the pre-clinical and discovery stages in the broad areas of inflammation and metabolic disorders.

The Company has generic formulation and API business interests in over 80 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Pediatrics, Gynecology, ENT, Cardiology, Diabetes and Oncology.

Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. The Company's second lead GRC 8200, a DPP-IV inhibitor for Type II Diabetes was out-licensed to Merck KGaA, Germany for the North American, European and Japanese markets. A third molecule targeting pain, GRC 6211, undergoing Phase 2 clinical trials in Europe, has recently been out-licensed to Eli Lilly & company.

For further information, please contact:

Ms. Vasudha Jha

General Manager, Corporate Communications

Glenmark Pharmaceuticals Ltd.

Tel: [+91 22] 40189919 | Fax: [+91 22] 40189986

Email: media@glenmarkpharma.com

http://www.glenmarkpharma.com

About Crofelemer

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Crofelemer is in various stages of clinical development for four distinct product indications, one in Phase 3, two in Phase 2 and one in Phase 1.

Crofelemer has been tested in trials involving approximately 1500 patients in double-blind placebo-controlled, mostly published t
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly and Glenmark Pharmaceuticals Announce License Agreement
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
(Date:9/22/2014)... , Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... scheduled to present a corporate overview and update at ... September 26, 2014, at 11:30 a.m. Eastern Time (8:30 ... New York City . ... available under the investor relations section of Arena,s website ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... meeting in Valves and Structural Heart, the fifth annual ... the 28th to the 30th of September, 2014 at ... UK. , In the tradition of the pioneering work ... become an accepted clinical option, PCR London Valves is ... and structural heart. Through innovative technologies and their application ...
(Date:9/22/2014)... by the Cancer Science Institute of Singapore (CSI ... found that an increase in a gene known ... implicated in acute myelogenous leukaemia (AML), increasing the ... Professor Chng Wee Joo, Deputy Director and Senior ... the National University Cancer Institute, Singapore, the scientists ...
(Date:9/22/2014)... FL (PRWEB) September 22, 2014 ... than 2,000 physicians, today Clearwater Clinical ... ClearSCOPE Endoscope Adaptor for smartphones. ClearSCOPE ... video from virtually any endoscope and smartphone. , ... adaptor in response to frustrations over the cost, ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 PreDiabetes ... treatment, will work with companies to help employees learn ... development of diabetes as part of a collaboration with ... @ Work initiative. , PreDiabetes Centers Medical Director ... of Transportation in Austin on Tuesday, October 21st to ...
(Date:9/22/2014)... On Saturday, September 27, 2014, La Comunidad ... fitness fair ¡Vive tu vida! Get Up! Get Moving!® This ... better health and wellness for people of all ages and ... the public, will be held at Anson B. Nixon Park, ... 2:00 pm. , “This is a wonderful event each ...
Breaking Medicine News(10 mins):Health News:Announcing the 5th PCR London Valves, 2014 2Health News:Announcing the 5th PCR London Valves, 2014 3Health News:Announcing the 5th PCR London Valves, 2014 4Health News:Singapore researchers discover a gene that increases incidence of AML 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3
... -- The Human Genome Project, along with numerous parallel efforts ... fungal, and microbe genomes in the last few decades, has ... struggling to keep pace. Knowing gene sequences, after all, may ... actual manifestation of physical traits (or phenotypes) of an organism ...
... ... technical and medical market, announced today that Wiley-Blackwell has agreed to conduct a trial ... three-month trial is designed to test how SciVee products and services can supplement and ... , ...
... five cesareans due to ,failed inductions, researchers find , ... than doubles the risk of having a cesarean delivery, ... numbers to a link that experts have long suspected. ... said study author Dr. Deborah Ehrenthal, director of women,s ...
... ... a gated community on Costa Rica’s South Pacific coast – has announced it will partner ... will be dedicated to helping its residents discover health and rediscover vitality. , ... (PRWEB) June 22, 2010 -- Pegasus Star ...
... ... even sit up straight and then, one day, you,re able to run through a meadow ... the very first time when they join the Hippotherapy and Therapeutic Riding programs at CAN-TR ... and Siler City resident, Lisa Reynolds. , ...
... ... with these budget-conscious instruments. , ... (Vocus) June 22, 2010 -- Cole-Parmer introduces a new line of ... For specialists in process, production, and manufacturing facilities who count parts or add up ...
Cached Medicine News:Health News:New genetic analysis reveals principles of phenotypic expression 2Health News:Wiley-Blackwell Conducts Trial of SciVee Video Platform 2Health News:Wiley-Blackwell Conducts Trial of SciVee Video Platform 3Health News:Labor Induction May Boost C-Section Risk 2Health News:Labor Induction May Boost C-Section Risk 3Health News:Costa Rica Real Estate Project Takes a Holistic Approach to Health Care 2Health News:Costa Rica Real Estate Project Takes a Holistic Approach to Health Care 3Health News:Ponies Help Kids with Disabilities Focus on What They CAN Do 2Health News:Ponies Help Kids with Disabilities Focus on What They CAN Do 3Health News:Cole-Parmer Launches New Industrial Line of Symmetry Scales 2
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: